Long‐Term Outcomes of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction and Coexisting End‐Stage Renal Disease
- Published on 07/29/2024
- Reading time: 4 min.
Wan‐Ying Lin 1, Yu‐Hsuan Joni Shao 2,3,4, Andy F. Chiang 1, Chih‐Chieh Huang 5, Kim F. Chiang 6, Chao‐Shun Chan 7,8,9, Chun‐Yao Huang 7,8,9, Bu‐Yuan Hsiao 7,8,9
1
Department of Family Medicine
Taipei Medical University Hospital
Taipei
Taiwan
2
Graduate Institute of Biomedical Informatics, College of Medical Science and Technology
Taipei Medical University
Taipei
Taiwan
3
Office of Data Science, Health Data Analytics and Statistics Center
Taipei Medical University
Taipei
Taiwan
4
Clinical Big Data Research Center
Taipei Medical University Hospital
Taipei
Taiwan
5
Office of Data Science
Taipei Medical University
Taipei
Taiwan
6
Department of Medicine
Stanford University School of Medicine
Stanford
California
USA
7
Division of Cardiology and Cardiovascular Research Center, Department of Internal Medicine
Taipei Medical University Hospital
Taipei
Taiwan
8
Division of Cardiology, Department of Internal Medicine, School of Medicine
College of Medicine, Taipei Medical University
Taipei
Taiwan
9
Taipei Heart Institute
Taipei Medical University
Taipei
Taiwan
Abstract
Sacubitril/valsartan (Entresto) has proven therapeutic effects in heart failure (HF) patients, but its impact on those with advanced chronic kidney disease (CKD) remains unclear, particularly in HF patients with coexisting end‐stage renal disease (ESRD). This study aims to assess the long‐term survival of patients with heart failure with reduced ejection fraction (HFrEF) and coexisting ESRD treated with sacubitril/valsartan. A retrospective cohort study included 2,860...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Cardiology
Receive our newsletter to stay up to date with the latest news in Cardiology
